Emerging as a significant advance in the struggle against obesity, Retatrutide is capturing considerable attention . It combines properties of two known GLP-1 binding agonists, liraglutide, with an unique glucose-dependent incretin component. Initial study data have shown significant body reduction in individuals with obesity , potentially providin